Investigational drug · Phase 3
QVM149
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Asthma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "QVM149"
First trial start
2026
Aug 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QVM149", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "QVM149" as an intervention, largest first.
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
- Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + TiotropiumPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03158311 · 1,426 participants · Start Feb 5, 2018 · Primary completion Jul 12, 2019
Drug: QVM149; Salmeterol/fluticasone plus tiotropium · For: Asthma
Sites: Berazategui, Argentina; CABA, Argentina; Caba, Argentina · 163 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05776927 · 188 participants (planned) · Start Aug 4, 2026 · Primary completion Dec 30, 2028
Drug: QVM149; Salmeterol Xinafoate / Fluticasone Propionate and 2 more · For: Asthma
Sites: Rosario, Argentina; Strasbourg, France; Wesel, Germany · 27 sites in all
- Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03063086 · 116 participants · Start Jan 21, 2017 · Primary completion Aug 2, 2018
Drug: QVM149 150/50/80 μg o.d.; QVM149 150/50/160 μg o.d. and 1 more · For: Asthma
Sites: Sofia, Bulgaria; Changchun, China; Tianjin, China · 12 sites in all
- A Long-term Safety Study of QVM149 in Japanese Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03100825 · 96 participants · Start Apr 28, 2017 · Primary completion Sep 18, 2018
Drug: QVM149 · For: Asthma
Sites: Koga, Japan; Yanagawa, Japan; Maebashi, Japan · 25 sites in all
- A Long-term Safety Study of QMF149 in Japanese Participants With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03100500 · 51 participants · Start Apr 25, 2017 · Primary completion Jul 19, 2018
Drug: QMF149 · For: Asthma
Sites: Nagoya, Japan; Fukuoka, Japan; Chitose, Japan · 15 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT03108027 · 38 participants · Start Jun 26, 2017 · Primary completion Feb 24, 2018
Drug: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose); Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose) and 1 more · For: Asthma
Sites: Berlin, Germany; Frankfurt Am Main Hessen, Germany; Großhansdorf, Germany · 7 sites in all
- Anti-inflammatory Effects GlycopyrroniumPivotal-lookingCompleted
University Medical Center GroningenAcademic, hospital or other
NCT04259164 · 28 participants · Start Sep 10, 2020 · Primary completion Dec 29, 2022
Drug: QVM149; QMF149 · For: Asthma; Allergic Asthma
Sites: Groningen, Netherlands
- Investigating the Effects of QVM149 on MRI Ventilation DefectsPivotal-lookingWithdrawn
Dr. Grace ParragaAcademic, hospital or other
NCT04206761 · 0 participants · Start Dec 1, 2021 · Primary completion Jul 1, 2022
Drug: QVM149; High Dose Dual Therapy (ICS/LABA) · For: Asthma
Sites: London, Canada
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.